Bone Marrow Transplantation in Low-Grade Non-Hodgkin's Lymphoma

References

• National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for clinical usage. The Non-Hodgkin Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Horning S. J., Rosenberg S. A. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Rohatiner A. Z. S., Lister T. A. Myeloablative therapy for follicular lymphoma. Hematol. Oncol. Clin. NA 1991; 5: 1003–1012
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Validity of Ann Arbor staging of the non-Hodgkin's lymphomas. Cancer Treat. Rep. 1977; 61: 1023–1027
   PubMedGoogle Scholar
• McLaughlin P., Fuller I. M., Velasquez W. S., et al. Stage HI follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J. Clin. Oncol. 1987; 5: 867–874
   PubMed Web of Science ®Google Scholar
• Rodgers R., McLaughlin P., Sullivan J., et al. Prognostic factors in stage IV nodular lymphoma (abstract). Proc. Am. Soc. Clin. Oncol. 1983; 2: 217
   Google Scholar
• Young R. C., Longo D. L., Glatstein E., et al. The treatment of indolent lymphomas: watchful waiting vs aggressive combined modality treatment. Semin. Hematol. 1988; 25(Suppl 2)11–16
   PubMed Web of Science ®Google Scholar
• Portlock C. S. “Good risk” non-Hodgkin's lymphomas: approaches in management. Semin. Hematol. 1983; 20: 25–34
   PubMed Web of Science ®Google Scholar
• Gallagher C. J., Gregory W. M., Jones A. E., et al. Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Weisdorf D. J., Andersen J. W., Glick J. H., Oken M. M. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J. Clin. Oncol. 1992; 10: 942–947
   PubMed Web of Science ®Google Scholar
• Longo D. L., Young R. C., Hubbard S. M., et al. Prolonged initial remission in patients with nodular mixed lymphoma. Ann. Intern. Med. 1984; 100: 651–656
   PubMed Web of Science ®Google Scholar
• Armitage J. O. Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Dick F. R., Corder M. P. Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat. Rep. 1992; 65: 413–418
   Google Scholar
• Astray S., Digs C., Sutherland J. C., et al. Nodular poorly differentiated lymphocytic lymphoma: changes in histology and survival. Cancer Treat. Rep. 1981; 65: 11–12
   PubMedGoogle Scholar
• Acker B., Hoppe R. T., Colby T. V., et al. Histologic conversion in the non-Hodgkin's lymphomas. J. Clin. Oncol 1983; 1: 11–16
   PubMed Web of Science ®Google Scholar
• Garvin A. J., Simon R. M., Osborne C. K., et al. An autopsy study of histologic progression in non-Hodgkin's lymphoma. 192 cases from the National Cancer Institute. Cancer 1983; 52: 393–398
   PubMed Web of Science ®Google Scholar
• Hubbard S. M., Chabner B. A., De Vita V. T., et al. Histologic progression in non-Hodgkin's lymphoma. Blood 1982; 59: 258–264
   PubMed Web of Science ®Google Scholar
• Landberg T. G., Hakansson L. G., Moller T. R., et al. CVP-remission-maintenance in stage I and II non-Hodgkin's lymphomas: preliminary results of a randomized study. Cancer 1979; 44: 831–838
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Fuller L. M., Velasquez W. S., et al. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58: 1596–1602
   PubMed Web of Science ®Google Scholar
• Nissen N. I., Ersboll J., Hansen H. S., et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 1983; 52: 1–7
   PubMed Web of Science ®Google Scholar
• Reddy S., Saxena V. S., Pellettiere E. V., Hendrickson F. R. Early nodal and extra nodal non-Hodgkin's lymphomas. Cancer 1977; 40: 98–104
   PubMed Web of Science ®Google Scholar
• Richards M. A., Gregory W. M., Hall P. A., et al. Management of localized non-Hodgkin's lymphoma: the experience at St. Bartholomew's Hospital 1972–1985. Haematol Oncol. 1989; 7: 1–18
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Dahlberg S., Miller T. P., et al. Long term survival of patients with nodular histiocytic, diffuse poorly differentiated lymphocytic, diffuse mixed, and diffuse undifferentiated lymphoma treated with CHOP chemotherapy (abstract #1003). Proc. Am. Soc. Clin. Oncol. 1989; 8: 257
   Google Scholar
• Ezdinli E. Z., Anderson J. R., Melvin F., et al. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J. Clin. Oncol. 1985; 3: 769–775
   PubMed Web of Science ®Google Scholar
• Kaufman J. H., Ezdinli E., Aungst C. W., Stutzman L. Lymphosarcoma: a comparison of extended to conservative chemotherapy. Cancer 1976; 37: 1283–1292
   PubMed Web of Science ®Google Scholar
• McKelvey E. M., Gottlieb I. A., Wilson H. E., et al. Hydroxyldaunomycin (Adriamycin)combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Steward W. P., Crowther D., McWilliams I. J., et al. Maintenance chlorambucil after CVP in the management of advanced stage, lowgrade histologic type non-Hodgkin's lymphoma. Cancer 1988; 61: 441–447
   PubMed Web of Science ®Google Scholar
• Peterson B. A., Anderson J. R., Frizzera G., et al. Combination chemotherapy prolongs survival in follicular mixed lymphoma (FML) (abstract #1004). Proc. Am. Soc. Clin. Oncol. 1990; 9: 259
   Google Scholar
• Garcia Zueco J. C., Delgado M. P., Giraldo M. P., et al. Non-Hodgkin's lymphomas. II. Analysis of the prognostic factors in a series of 307 patients. Sangre 1992; 37: 337–344
   PubMedGoogle Scholar
• Surbone A., Armitage J. O., Gale R. P. Autotransplantation in lymphoma: better therapy or healthier patients?. Ann. Intern. Med 1991; 114: 059–1060
   PubMedGoogle Scholar
• Fisher R. I., Gamer E. R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Gordon L. I., Harrington D., Andersen J., et al. Comparison of a second-generation combination chemotherapy regimen (M-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med. 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Epelbaum R., Haim N., Ben-Shahar M., et al. Dose intensity for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr. J. Med. Sci. 1988; 24: 533–537
   PubMedGoogle Scholar
• DeVita V. T., Jr., Hubbard S. M., Longo D. L. The chemotherapy of lymphomas: Looking backward, moving forward-The Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987; 47: 5810–5824
   PubMed Web of Science ®Google Scholar
• Kwak L. W., Halpem J., Olshen R. A., et al. Prognostic significance and actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J. Clin. Oncol. 1990; 8: 963–977
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Velasquez W. S., McLaughlin P., et al. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin. Hematol. (suppl 2) 1988; 25: 47–50
   PubMed Web of Science ®Google Scholar
• Zuckerman K. S., LoBuglio A. F., Reeves J. A. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high dose doxorubicin-containing regimen. J. Clin. Oncol. 1990; 8: 248–256
   PubMed Web of Science ®Google Scholar
• Sweetenham J. W., Mead G. M., Whitehouse J. M. A. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 1991; 9: 2202–2209
   PubMed Web of Science ®Google Scholar
• Gulati S. C., Shank B., Black P., et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J. Clin. Oncol. 1988; 6: 1303–1313
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. O., Bierman P. J., et al. Salvage therapy for relapsed or refractory non-Hodgkins' lymphoma utilizing autologous bone marrow transplantation. Am. J. Med. 1987; 87: 285–287
   Web of Science ®Google Scholar
• Takvorian T., Canellos G. P., Ritz J., et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N. Engl. J. Med. 1987; 87: 1499–1505
   Web of Science ®Google Scholar
• Goldstone A. H., Gribben J. G., McMillan A. K., et al. The sixth report of the EBMTG registry of ABMT in lymphomas (abstract). Bone Marrow Transplant 1989; 4(Suppl 2)53
   PubMedGoogle Scholar
• Philip T., Armitage J. O., Spitzer G., et al. High-dose therapy and autologous bone marrow transplantation alter failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Fay J. W., Herzig R. H., et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood. 1990; 75: 831–838
   PubMed Web of Science ®Google Scholar
• Petersen F. B., Appelbaum F. R., Hill R., et al. Autologous bone marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J. Clin. Oncol. 1990; 8: 638–647
   PubMed Web of Science ®Google Scholar
• Colombat P., Gorin N.-C, Lemonnier M.-P., et al. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 1990; 8: 630–637
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Goldstone A. H., Linch D. C., et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who are still responsive to conventional dose chemotherapy. J. Clin. Oncol. 1989; 7: 1621–1629
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Takvorian T., Anderson K. C., et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J. Clin. Oncol. 1990; 8: 784–791
   PubMed Web of Science ®Google Scholar
• Lazarus H. M., Crilley P., Ciobanu N., et al. High-dose carmustine. etoposide. and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J. Clin. Oncol. 1992; 10: 1682–1689
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Sullivan K. M., Buckner C. D., et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J. Clin. Oncol. 1987; 5: 1340–1347
   PubMed Web of Science ®Google Scholar
• Chopra R., Goldstone A. H., Pearce R., et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group registry data. J. Clin. Oncol. 1991; 10: 1690–1695
   Web of Science ®Google Scholar
• Hurd D. D., Le Bien T. W., Lasky L., et al. Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. Am. J. Med. 1988; 85: 829–834
   PubMed Web of Science ®Google Scholar
• Schouten H. C., Bierman P. J., Vaughan W. P., et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood. 1989; 74: 2579–2584
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Ritz J., Neuberg D., et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524–2529
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Rowlings P. A. Unpublished observations of the North American Autologous Bone Marrow Transplant Registry. 1993
   Google Scholar
• Bierman P., Vose J., Armitage J., et al. High-dose therapy followed by autologous hematopoietic rescue for follicular low grade non-Hodgkin's lymphoma (NHL) (abstract #1074). Proc. Am. Sot: Clin. Oncol., 11: 317
   Google Scholar
• Vose J. M., Bierman P. J., Anderson J. R., et al. High-dose chemotherapy with hematopoietic stem cell rescue for non-Hodgkin's lymphoma: evaluation of event-free survival based on histologic subtype and rescue product. Proc. Am. Sot: Clin. Oncol. 1992; 11: 318
   Google Scholar
• Weisdorf D. J., Haake R., Miller W. J., et al. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotyping and in vitro purging. Bone Marrow Transplant, 8: 135–142
   PubMed Web of Science ®Google Scholar
• Simon R., Durrleman S., Hoppe R. T., et al. The Non-Hodgkin Lymphoma Pathologic Classification Project: Long-term follow-up of 1153 patients with non-Hodgkin's lymphomas. Ann. Intern. Med. 1988; 109: 939–945
   PubMed Web of Science ®Google Scholar
• Anderson T., Chabner B. A., Young R. C., et al. Malignant lymphoma. I. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2699–2707
   PubMed Web of Science ®Google Scholar
• Jones S. E., Fuks Z., Bull M., et al. Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer 1973; 31: 806–823
   PubMed Web of Science ®Google Scholar
• Bearman S. I., Appelbaum F. R., Back A., et al. Regimenrelated toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J. Clin. Oncol. 1989; 7: 1288–1294
   PubMed Web of Science ®Google Scholar
• To L. B., Roberts M. M., Haylock D. N., et al. Comparison of haematologic recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992; 9: 277–284
   PubMed Web of Science ®Google Scholar
• Haas R., Ho A. D., Bredthauer U., et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp. Hematol. 1990; 18: 94–98
   PubMed Web of Science ®Google Scholar
• Kessinger A., Armitage J. O. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood. 1991; 77: 211–213
   PubMed Web of Science ®Google Scholar
• Kessinger A., Vose J. M., Bierman P. J., Armitage J. O. High-dose chemotherapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging. Exp. Hematol. 1991; 19: 1013–1016
   PubMed Web of Science ®Google Scholar
• Vose J. M., Bierman P. J., Armitage J. O. High dose chemotherapy with stem cell rescue for the treatment of follicular low grade non-Hodgkin's lymphoma. Autologous Bone Marrow Transplantation. V. Proceedings of the Fifth International Symposium, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger. University of Nebraska Medical Center Press, Omaha 1991; 479–485
   Google Scholar
• Körbling M., Holle R., Haas R., et al. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J. Clin. Oncol. 1990; 8: 978–985
   PubMed Web of Science ®Google Scholar
• Pecego R., Hill R., Appelbaum F. P., et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986; 42: 515–517
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Wolff S. N., Herzig R. H., et al. The treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1989; 73: 2086–2092
   PubMed Web of Science ®Google Scholar
• Foucar K., McFenna R. W., Frizzera C., et al. Incidence and patterns of bone marrow involvement by lymphoma in relation to the Lukes-Collins classification. Blood 1979; 54: 1417–1422
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Bone marrow involvement in the non-Hodgkin's lymphomata. Br. J. Cancer, (suppl 2) 1975; 31: 261–264
   Web of Science ®Google Scholar
• Stein R. S., Ultmann J. E., Byrne G. E., et al. Bone marrow involvement in non-Hodgkin's lymphoma: implications for staging and therapy. Cancer 1976; 37: 629–636
   PubMed Web of Science ®Google Scholar
• Chabner B. A., Johnson R. E., Young R. C., et al. Sequential nonsurgical and surgical staging on non-Hodgkin's lymphoma. Ann. Intem. Med. 1976; 85: 149–154
   PubMed Web of Science ®Google Scholar
• Smith B. R., Weinberg D. S., Robert N. I., et al. Circulating monoclonal B lymphocytes in non-Hodgkin's lymphoma. N. Engl. J. Med. 1984; 311: 1476–1481
   PubMed Web of Science ®Google Scholar
• Nakano M., Kawanishi Y., Kuge S., et al. Clinical and prognostic significance of monoclonal small cells in the peripheral blood and bone marrow of various B-cell lymphomas. Blood 1992; 79: 3253–3260
   PubMed Web of Science ®Google Scholar
• Bortin M. M., Horowitz M. M., Rimm A. A. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988–1990 survey. Ann. Intern. Med 1992; 116: 505–512
   PubMed Web of Science ®Google Scholar
• Gale R. P., Bortin M. M., van Bekkum D. W., et al. Risk factors for acute graft-versus-host disease. Br. J. Haematol. 1987; 67: 397–406
   PubMed Web of Science ®Google Scholar
• Atkinson K., Horowitz M. M., Gale R. P., et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459–2464
   PubMed Web of Science ®Google Scholar
• Jones R. J., Ambinder R. F., Piantadosi S., Santos G. W. Evidence of a graft-versus-lymphomaeffect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Johnson S. A., Catovsky D., et al. Identical twin marrow transplantation for patients with leukemia and lymphoma. Transplantation 1981; 31: 140–141
   PubMedGoogle Scholar
• Lu C., Braine H. G., Kaizer H., et al. Preliminary results of highdose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat. Rep. 1984; 68: 711–717
   PubMedGoogle Scholar
• Appelbaum F. R., Thomas E. D., Buckner C. D., et al. Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogeneic marrow transplantation. Hematol. Oncol. 1983; 1: 149–157
   PubMedGoogle Scholar
• Copelan E. A., Kapoor N., Gibbins B., Tutschka P. J. Allogeneic marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplantation 1990; 5: 47–50
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Fefer A., Cheever M. A., et al. Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. Blood 1981; 58: 509–513
   PubMed Web of Science ®Google Scholar
• Goldstone A. H., Pearce R., Personal communication
   Google Scholar
• Kwok S., Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237–238
   PubMed Web of Science ®Google Scholar
• Limpins J., de Jong D., van Krieken J. H. J. M., et al. Bcl-2/Jh rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991; 6: 2271–2276
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Rill D. R., Moan R. C., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Rill D. R. Gene marking to improve the outcome of autologous bone marrow transplantation. J. Hematother. 1994; 3: 33–36
   PubMedGoogle Scholar
• Alperi M. A., Lopez M., Douay L., et al. Clonogenic leukemic progenitor cells in acute myelocytic leukemia are highly sensitive to cryopreservation: possible purging effect for autologous bone marrow transplantation. Bone Marrow Transplant 1991; 7: 101–105
   Web of Science ®Google Scholar
• Price C. G. A., Meerabux J., Murtagh S., et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J. Clin. Oncol. 1991; 9: 1527–1532
   PubMed Web of Science ®Google Scholar
• Goldstone A. H. Unpublished observations of the European Bone Marrow Transplant Registry. Presented at the First Annual Meeting of the North American Autologous Bone Marrow Transplant Registry, Keystone, Colorado, 1992
   Google Scholar
• Gribben J. G., Freedman A. S., Neuberg D., et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Weiss L. M., Warnke R. A., Sklar J., Cleary M. L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N. Engl. J. Med 1985; 317: 1185–1189
   Web of Science ®Google Scholar
• Yunis J. J., Oken M. M., Kaplan M. E., et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N. Engl. J. Med 1982; 307: 1231–1236
   PubMed Web of Science ®Google Scholar
• Ngan B. Y., Nourse J., Cleary M. L. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989; 73: 1759–1762
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A. F., Woo S. D., et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable bcl-2 translocation have residual cells containing the bcl-2 rearrangement at evaluation and following treatment. Blood 1991; 78: 3275–3280
   PubMed Web of Science ®Google Scholar
• European Bone Marrow Transplant Registry. Randomized trial in low-grade non-Hodgkin's lymphoma: purge vs no purge. 1993
   Google Scholar
• Freedman A. S., Ritz J., Anderson K. C., . Autologous bone marrow transplantation in low grade B cell non-Hodgkin's lymphoma. Autologous Bone Marrow Transplantation. V. Proceedings of the Fifth International Symposium, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger, et al. University of Nebraska Medical Center Press, Omaha 1991; 453–463
   Google Scholar
• Rohatiner A. Z. S., Price C. G. A., Amott S., . Ablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. Autologous Bone Marrow Transplantation. V. Proceedings of the Fifth International Symposium, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger, et al. University of Nebraska Medical Center Press, Omaha 1991; 465–471
   Google Scholar
• Rohatiner A. Z. S., Lister T. A. Myeloablative therapy for follicular lymphoma. Hematol. Oncol. Clin. NA 1991; 5: 1003–1012
   PubMed Web of Science ®Google Scholar
• Rohatiner A. Z. S., Freedman A., Nadler I., et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma (abstract #38). Proceedings of the 5th International Conference on Lymphoma, LuganoSwitzerland, 1993
   Google Scholar
• Vose, J. Personal communication. Data presented at the 6th International Symposium on Autologous Bone Marrow Transplantation, Houston, Texas, 1992
   Google Scholar
• Colombat P., Biron P., Binet C., . High dose chemotherapy with autologous bone marrow transplantation in low grade non-Hodgkin's lymphomas. Autologous Bone Marrow Transplantation. IV. Proceedings of the Fourth International symposium, K. A. Dicke, G. Spitzer, S. Jagannath, M. J. Evinger Hodges, et al. The University of Texas. M. D. Anderson Cancer Center, Houston 1989; 317–325
   Google Scholar
• Colombat P., Desbois I., Biron P., et al. Results of high dose chemotherapy with autologous bone marrow transplantation in 16 cases of follicular lymphoma (abstract). Exp. Hematol. 1989; 17: 585
   Google Scholar
• Horning S. J. 1993, Personal communication
   Google Scholar
• Fouillard L., Gorin N., Laporte I., et al. Feasibility of autologous bone marrow transplantation for early consolidation of follicular non-Hodgkin's lymphoma. Eur. J. Haematol. 1991; 46: 279–284
   PubMed Web of Science ®Google Scholar
• Fouillard L., Gorin N. C., Laporte J. P., . A possible new approach to the management of follicular non-Hodgkin's lymphoma: early autologous bone marrow transplantation for consolidation in first remission. Autologous Bone Marrow Transplantation. V. Proceedings of the Fifth International Symposium, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger, et al. University of Nebraska Medical Center Press, Omaha 1991; 473–478
   Google Scholar
• Higuchi C. M., Thompson J. A., Cox T., et al. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematologic malignancies. Cancer Res. 1989; 49: 5509–5513
   PubMed Web of Science ®Google Scholar
• Reittie J. E., Gottlieb D., Heslop H. E., et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351–1358
   PubMed Web of Science ®Google Scholar
• Klingemann H.-G., Phillips G. L. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 1991; 8: 73–81
   PubMed Web of Science ®Google Scholar
• Ascensao J. L., Miller K. B., Tuck D., et al. Immunotherapy with recombinant human interferon alpha 2B (IFN) following autologous bone marrow transplantation (ABMT) for lymphomas: an update (abstract #1296). Proc. Am. Soc. Clin. Oncol. 1993; 12: 380
   Google Scholar
• Schenkein D. P., Dixon P., Ascensao J. L., et al. Autologous bone marrow transplantation using cyclophosphamide, carboplatin, etoposide with post-transplant α interferon for patients with Hodgkin's and non-Hodgkin's lymphoma. Proc of the 5th International Conference on Lymphoma, LuganoSwitzerland, 1993
   Google Scholar
• Klingemann H.-G, Grigg A. P., Wilkie-Boyd K., et al. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood. 1991; 78: 3306–3311
   PubMed Web of Science ®Google Scholar
• Nagler A., Ackerstein A., Or R., et al. Immunotherapy by recombinant alpha interferon (αIFN) and recombinant human in-terleukin-2(IL-2) of lymphoma patients post-autologous bone marrow transplantation (ABMTK)(abstract #262). Blood 1992; 80: 68a
   PubMedGoogle Scholar
• Heslop H. E., Gottleib D. J., Bianchi A. C., et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74: 1374–1380
   PubMed Web of Science ®Google Scholar
• Blaise D., Olive D., Stoppa A. M., et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092–1097
   PubMed Web of Science ®Google Scholar
• Gottlieb D. J., Brenner M. K., Heslop H. E., et al. A phase I clinical trial of recombinant interleukin-2 following high dose chemoradiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br. J. Cancer 1989; 60: 610–615
   PubMed Web of Science ®Google Scholar
• Gottlieb D. J., Prentice H. G., Heslop H. E., et al. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemoradiotherapy for hematologic malignancy. Blood. 1989; 74: 2335–2342
   PubMed Web of Science ®Google Scholar
• Higuchi C. M., Thompson J. A., Petersen F. B., et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood. 1991; 77: 2561–2568
   PubMed Web of Science ®Google Scholar
• Benyunes M., York A., Lindgren C., et al. 1L-2 LAK cells as consolidative therapy after autologous BMT for hematologic maligancies: a feasibility trial (abstract #1082). Proc. Am. Soc. Clin. Oncol. 1992; 11: 319
   Google Scholar
• Larsson E. L., Joki A. L., Stalhandske T. Mechanism of action of the new immunomodulator LS26I6 on T cell-responses. Int. J. Immunopharmacol 1987; 9: 425–431
   PubMed Web of Science ®Google Scholar
• Bengtsson M., Simonsson B., Carlsson K., et al. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1982; 53: 882–888
   Web of Science ®Google Scholar
• Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 1990; 144: 442–476
   Google Scholar
• Smalley R. V., Andersen J. W., Hawkins M. J., et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N. Engl. J. Med. 1992; 327: 1336–1341
   PubMed Web of Science ®Google Scholar
• Horning S. J., Merigan T. C., Known S. E., et al. Human interferon alpha in malignant lymphoma and Hodgkin's disease: results of the American Cancer Society trial. Cancer 1985; 56: 1305–1310
   PubMed Web of Science ®Google Scholar
• Foon K. A., Roth M. S., Bunn P. A., Jr. Alpha interferon treatment of low grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. Semin. Oncol. 1986; 13(Suppl 2)35–42
   Google Scholar
• Vander Molen L. A., Steis R. G., Duffey P. L., et al. Low-versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J. Natl. Cancer Inst. 1990; 82: 235–238
   PubMed Web of Science ®Google Scholar
• Carella A. M., Gaozza E., Congin A., et al. Cyclosporineinduced graft-versus-host disease after autologous bone marrow transplantation in hematologic malignancies. Ann. Hematol 1991; 62: 156–159
   PubMed Web of Science ®Google Scholar
• Jones R. J., Vogelsang G. B., Hess A. D., et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; i: 754–757
   Google Scholar
• Talbot D. C., Powles R. L., Sloane J. P., et al. Cyclosporineinduced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukemia. Bone Marrow Transplant. 1990; 6: 17–20
   PubMed Web of Science ®Google Scholar
• Yeager A. M., Vogelsang G. B., Jones R. J., et al. Induction of cutaneous graft-versus-dose disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031–3035
   PubMed Web of Science ®Google Scholar
• Kennedy M. J., Vogelsang G. B., Beveridge R. A., et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol. 1993; 11: 478–484
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Freedman A. S., Ritz J., et al. Serotherapy of B cell neoplasms with anti-B4 blocked ricin: a phase I trial of daily bolus infusion. Blood 1992; 79: 576–585
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Press O. W., Appelbaum F. R., et al. Perspective. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863–878
   PubMed Web of Science ®Google Scholar
• Mertlesmann R., Herrmann F., Hecht T., Schulz G. Review. Hematopoietic growth factors in bone marrow transplantation. Bone Marrow Transplant 1990; 6: 79–87
   PubMedGoogle Scholar
• Aurer I., Ribas A., Gale R. P. Review. What is the role of recombinant colony-stimulating factor in bone marrow transplantation?. Bone Marrow Transplant 1990; 6: 79–87
   PubMed Web of Science ®Google Scholar
• Lazarus H. M., Andersen J., Chen M. G., et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Group trial. Blood 1991; 78: 830–837
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., Rabinowe S. N., Singer J. W., et al. Recombinant granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for lymphoid cancer. N. Engl J. Med. 1991; 324: 1773–1778
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Coiffier B., Hayat M., et al. RHU GM-CSF shortens aplasia duration after ABMT in non-Hodgkin's lymphoma: a randomized placebo-controlled double-blind study (abstract). Bone Marrow Transplant 1991; 7(Suppl 2)82
   PubMedGoogle Scholar
• Gianni A. M., Tarella C., Siena S., et al. Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. Bone Marrow Transplant. 1990; 6: 143–145
   PubMed Web of Science ®Google Scholar
• Sheridan W. P., Begley C. G., Juttner C. A., et al. Effect of peripheral-blood progenitor cells mobilized by Filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–644
   PubMed Web of Science ®Google Scholar
• Peters W. P., Rosner G., Ross M., et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719
   PubMed Web of Science ®Google Scholar
• Chao N. J., Schriber J. R., Grimes K., et al. Granulocyte colony stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–2035
   PubMed Web of Science ®Google Scholar
• Kotasek D., Shepherd K. M., Sage R. E., et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17
   PubMed Web of Science ®Google Scholar
• Brügger W., Brass K., Frisch J., et al. Mobilization of peripheral blood progenitor cells by sequential administration of in-terleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 1992; 79: 1193–1200
   PubMed Web of Science ®Google Scholar
• Korbling M., Hans M. Transplantation of Hemapheresis-derived hemopoietic stem cells: a new concept in the treatment of patients with malignant lymphohemopoietic disorders. Plasma Titer. Transfus. Technol. 1988; 9: 119–132
   Google Scholar
• Ross A. A., Cooper B. W., Lazarus H. M., et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605–2610
   PubMed Web of Science ®Google Scholar
• Moss T. J., Sanders, Lasky D. U., L C., et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990; 76: 1879–1883
   PubMed Web of Science ®Google Scholar
• Sharp J. G., Armitage J., Crouse D., . Are occult tumor cells present in peripheral stem cell harvests of candidates for autologous transplantation?. Autologous Bone Marrow Transplantation. IV. Proceedings of the Fourth International Symposium, K. A. Dicke, G. Spitzer, S. Jagannath, M. I. Evinger-Hodges, et al. The University of Texas, M. D. Anderson Cancer Center, Houston 1989; 693–696
   Google Scholar
• Körbling M., Fliedner T. M., Holle R., et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (PABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991; 7: 343–349
   PubMed Web of Science ®Google Scholar
• Brice P., Marolleau J. P., Dombret H., et al. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas. Bone Marrow Transplant 1992; 9: 337–342
   PubMed Web of Science ®Google Scholar
• Brugger W., Brass K. J., Giant M., Weber F., Mertelsmann R., Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636–640
   PubMed Web of Science ®Google Scholar
• Robbins R. A., Linder J., Stahl M. G., et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am. J. Med. 1989; 87: 511–518
   PubMed Web of Science ®Google Scholar
• Metcalf J. P., Rennard S. I., Reed E. C., et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. Am. J. Med. 1994; 96: 327–334
   PubMed Web of Science ®Google Scholar
• Juckett M., Perry E. H., Daniels B. S., Weisdorf D. J. Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1991; 7: 405–409
   PubMed Web of Science ®Google Scholar
• Guinan E. C., Tarbell N. J., Niemeyer C. M., et al. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1988; 72: 451–455
   PubMed Web of Science ®Google Scholar
• Vose J., Darrington D., Bierman P., et al. Myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) following high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancy: characterization and relative risk (abstract #42). Proceedings of the 5th International Conference on Lymphoma, LuganoSwitzerland, 1993
   Google Scholar
• Armitage J., Vose J., Anderson J., et al. Complete remission (CR) following high-dose chemotherapy (HDC) and autologous hematopoietic rescue for non-Hodgkin's lymphoma (NHL): evaluation of CR durability and incidence of secondary myelodysplastic syndrome (abstract # 1225). Proc. Am. Sot: Clin. Oncol. 1993; 12: 363
   Google Scholar
• Saven A., Piro L. D. The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies. Cancer 1993; 72(suppl 11)3470–3483
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Lauria F., Rondelli D., et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann. Oncol. 1993; 4: 575–578
   PubMed Web of Science ®Google Scholar
• Whelan J. S., Davis C. L., Rule S., et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy, fir. J. Cancer 1991; 64: 120–123
   Web of Science ®Google Scholar
• Hiddemann W., Unterhalt M., Pott C., et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin. Oncol. 1993; 20 (suppl 7): 28–31
   Web of Science ®Google Scholar
• Hochster H. S., Kim K. M., Green M. D., et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 1992; 10: 28–32
   PubMed Web of Science ®Google Scholar
• Redman J. R., Cabanillas F., Velasquez W. S., et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J. Clin. Oncol. 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• O'Dwyer P. J., Wagner B., Leyland-Jones B., Wittes R. E., Cheson B. D., Hoth D. F. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rationale development of an active new drug. Ann. Intern. Med. 1988; 108: 733–743
   PubMed Web of Science ®Google Scholar
• O'Dwyer P. J., Cheson B. D., Leyland-Jones B., et al. Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia. Oncology 1988; 2: 17–27
   PubMedGoogle Scholar
• Cummings F. J., Kim K., Neiman R. S., et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J. Clin. Oncol. 1991; 9: 565–571
   PubMed Web of Science ®Google Scholar
• Saven A., Piro L. D. 2-chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann. Intern. Med. 1994; 120: 784–791
   PubMed Web of Science ®Google Scholar
• Kay A. C., Saven A., Carrera C. J., et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Homing S. J. Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881–884
   PubMed Web of Science ®Google Scholar